Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Regeneron Pharmaceuticals Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
REGN
Nasdaq
8731
https://www.regeneron.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Regeneron Pharmaceuticals Inc
Down -8.24% in 4 Weeks, Here's Why Regeneron (REGN) Looks Ripe for a Turnaround
- Apr 29th, 2024 1:35 pm
Countdown to Regeneron (REGN) Q1 Earnings: A Look at Estimates Beyond Revenue and EPS
- Apr 29th, 2024 1:16 pm
EYLEA® HD (aflibercept) Injection 8 mg Presentations at ARVO Reinforce Sustained and Clinically Meaningful Outcomes in Serious Retinal Diseases
- Apr 29th, 2024 11:00 am
11 Oversold Growth Stocks to Buy Right Now
- Apr 28th, 2024 10:32 pm
Heard on the Street: Bristol-Myers Goes From Big Pharma to Little Pharma
- Apr 25th, 2024 3:42 pm
EXEL vs. REGN: Which Stock Is the Better Value Option?
- Apr 25th, 2024 3:40 pm
Regeneron (REGN) Reports Next Week: What You Should Expect
- Apr 25th, 2024 2:02 pm
UPDATE 1-AbbVie's skin disease drug found to be more effective than Regeneron's Dupixent in study
- Apr 25th, 2024 12:44 pm
The Zacks Analyst Blog Highlights Danaher, Regeneron Pharmaceuticals, Palo Alto Networks, Workday and American Electric Power
- Apr 25th, 2024 12:44 pm
Regeneron and Mammoth Biosciences Collaborate to Pursue Next-Generation CRISPR-Based Gene Editing for Multiple Diseases
- Apr 25th, 2024 11:00 am
Regeneron to collaborate on gene editing therapies with Doudna-founded Mammoth
- Apr 25th, 2024 11:00 am
Regeneron expands in gene editing with Mammoth deal
- Apr 25th, 2024 7:00 am
Top Stock Reports for Danaher, Regeneron Pharmaceuticals & Palo Alto Networks
- Apr 24th, 2024 7:51 pm
Regeneron to Showcase Progress in Advancing Novel Investigational Treatment Approaches for a Broad Range of Solid Tumors and Blood Cancers at ASCO
- Apr 24th, 2024 2:05 pm
Regeneron to Highlight Advances in Genetic Medicine Research at American Society of Gene and Cell Therapy (ASGCT)
- Apr 22nd, 2024 9:54 pm
Agenus (AGEN) Soars 6.8%: Is Further Upside Left in the Stock?
- Apr 22nd, 2024 8:17 am
Regeneron Pharmaceuticals Insiders Sell US$26m Of Stock, Possibly Signalling Caution
- Apr 19th, 2024 2:00 pm
Biotech Stock Roundup: REGN, SAGE, NMRA Down on Updates, ITCI Gains on Study Success
- Apr 18th, 2024 5:55 pm
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
- Apr 17th, 2024 1:00 pm
Why Regeneron (REGN) Could Beat Earnings Estimates Again
- Apr 16th, 2024 4:10 pm
Scroll